Equinox Gold shares surge following record-breaking production year
The miner produced 213,906 ounces of gold in the fourth quarter and 621,870 ounces for the full year.
(via TheNewswire)
Daren Graham, Executive Chairman of Rize Oncology, stated, “This name change reflects our evolution as a company and our unwavering commitment to advancing breakthrough treatments for soft tissue sarcoma. With the recent addition of STS-201 to our pipeline, we have a unique opportunity to address critical unmet needs in soft tissue sarcoma and beyond. As we focus on advancing this promising program, we are ensuring our corporate identity fully aligns with our mission and vision.”
STS-201 is a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, as well as other types of cancers and certain proliferative diseases. The unique mechanism of action of STS-201 results in:
A blockade of cell division at the late G/M boundary, a site in the cell cycle that is believed to be optimal for radiation-induced damage.
A slowing of the rate of tumor proliferation, which enables normalization of the tumor neo-vasculature. The result is better oxygenation and more efficient drug delivery.
Increased oxygen in the tumor micro-environment, which increases sensitivity to radiation due to radiation-induced formation of reactive oxygen species.
Formation of a more complete tumor vasculature, which reduces the poorly formed, disorganized vascular sites where metastatic cells penetrate the circulatory system.
For more information about Rize Oncology, visit www.rizeoncology.com.
About Soft Tissue Sarcoma
Soft tissue sarcomas are a rare, diverse and often rapidly fatal group of tumors consisting of more than 100 different subtypes that are estimated to account for about 1% of all cancers in adults and 7% in children. Treatment of STS is an immediate unmet medical need. STS tumors can occur anywhere within the body, including muscle, fat, nerves, vascular tissue, and other connective tissues. Median survival after development of distant metastases is estimated to be 11 to 18 months, but this varies significantly based on primary histologic subtype and treatment paradigms. Based on the prevalence of STS in the United States, Rize believes it is a rare disease and that STS-201 for the treatment of STS may qualify for Orphan Drug status.
About Rize Oncology Inc.
Rize Oncology Inc. is a pharmaceutical company dedicated to developing innovative oncology therapies. With a focus on advancing treatments for soft tissue sarcoma, Rize Oncology aims to make a meaningful impact on patients' lives by Turning the Tide on Metastasis. For more information, please visit www.rizeoncology.com.
Contact:
Roland Boivin, CEO (833) 294-4363 ext. 1 [email protected]
Daren Graham, Executive Chairman
(833) 294-4363 ext. 2
Forward-Looking Statements
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Rize’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include the Company’s expectations concerning STS-201 and its ability to address unmet needs in soft tissue sarcomas, its expectation that STS-201 may qualify for orphan drug status and all other statements that are not statements of historical fact.
Although Rize believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of Rize to implement its business strategies; competition; the ability of Rize to obtain and retain all applicable regulatory and other approvals and other assumptions, risks and uncertainties that may be disclosed in the Company’s continuous disclosure record from time to time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
Neither the Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release.
Copyright (c) 2025 TheNewswire - All rights reserved.
